medRxiv PreprintsInternational18 November 2026
α-synuclein seed amplification assay positivity is associated with motor progression in the prodromal stage independent of phenoconversion
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Abstract Background: -Synuclein seed amplification assay (Syn-SAA) has emerged as a promising biomarker for detecting underlying -synuclein pathology and predicting phenoconversion in prodromal Parkinson's disease (PD). However, its association with longitudinal clinical progression during the prodromal stage remains unclear. We investigated whether baseline Syn-SAA status and kinetic parameters were associated with motor and cognitive progression and subsequent phenoconversion in prodromal individuals. Methods: Clinical progression was assessed using the Movement Disorder Society-Sponsored Re
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.